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• 62,645 new cases from 2011-2015 alone
Mortality: 2.3/100,000/year
• 20,673 deaths from 2011-2015
• 5 year survival rate: 67%
Screening:
• Pap smear:
• Provider collects cells via swab at outer opening of 
cervix
• Cells are observed for precancerous changes  
• High Risk HPV testing:
• Identifies if DNA of high risk HPV types are present in 
cervical cells
• 70% of cervical cancer can be attributed to just two HPV 
types: 16 and 18
HPV: the primary cause of cervical cancer
• Most common STI in the US (Incidence: 14million/year)
• >200 identified HPV types, ~40 preferentially effect genital 
mucosa
• Often transient, but some HPV types tend to persist
• Persistent HPV infection can induce cell abnormalities leading 
to cervical cancer
• HPV is not a reportable disease (except in some states)



























































































Cervical Cancer Incidence & Mortality
Incidence Mortality








Women aged <21 years No screening
D
Women aged 21 - 29 years Cervical cytology alone every 3 
years A




high risk HPV testing‡ alone 
every 5 years
OR
Co-testing (high risk HPV testing‡ 
and cervical cytology) every 5 
years




Women who have had a 
hysterectomy with removal 
of the cervix and do not have 
a history of high-grade 


















2015 2016 2017 2018
Percent of Eligible Women up to Date on Cervical Cancer Screening
Hudson Headwaters Health Network National Health Interview Survey (self-reported)
Healthy People 2020 National Goal
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Public Health Cost
$8.0 billion annual direct cost burden HPV-associated 
disease: 
• $6.6 billion (82.3%): routine cervical cancer screening and 
follow-up
• $1.0 billion (12.0%): cancer 
• $0.4 billion for cervical cancer
• $0.3 billion for oropharyngeal cancer
• $0.3 billion (3.6%): genital warts
• $0.2 billion (2.1%): recurrent respiratory papillomatosis
This Photo by Unknown Author is licensed under CC BY-NC-ND
6
“As with a lot of diseases, there continues to be many people that 
don’t think getting a diagnosis of cervical cancer will happen to them. 
~ Linda Spokane (VP, Population Health Management, Hudson Headwaters)
Community Perspective
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Key Points from discussions with primary care providers
• Patients dislike receiving prompts for screening when visiting 
for an unrelated reason
• Screening appointments made by providers leads to no-shows
• OB/GYN visits generally imply the possibility of screening
There is a lot of confusion over what causes cervical cancer, who gets it, and why it’s 
critical to seek treatment when any abnormalities are detected. Especially with the new 
guidelines around the frequency recommended for pap smears, there are conflicting 
messages patients are hearing about how to protect themselves. 
~  Emma Corbett (VP of Communications, Planned Parenthood Mohawk Hudson)
Intervention 
Development

























• 2019 WMH2 Data
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“Preventive care for women. Does the sex of 
the physician matter?” Lurie, et al. 
Method: 
• Midwest US, 1990
• 97,962 women
• 18 to 75 years of age
• Pap smear frequency 
for each physician 
calculated against 
number of women in 
his or her practice.
Results:
• Pap smears with 
female physicians 
compared to male 
physicians
• OR = 1.99
• 95% CI: 1.72 to 2.30
Authors’ conclusions: 
• Women are more 
likely to undergo 
screening with Pap 
smears if they see 
female rather than 
male physicians
• Particularly if the 
physician is an 
internist or family 
practitioner.
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Patients of Providers w/ 
<50% Screening Rate: 2,260 
(11.8% of Total Patients)
Patients of Providers with 
>50% Screening Rate: 16,889
Providers w/ >50% 
Screening Rate: 72




















High percentage of people missing screening
Represents high percentage of population lacking screening
Trends:
• Income range, chronic conditions, BMI group, age 
range, insurance type
• No trend
• Mammogram rates: positive trend
• Women >50 that had mammograms were more likely 
to have pap smear
• PHQ-9 Score: negative trend
• Except for unscored patients
• Most at risk population: 29-32% missing screening
• 1% of population lacking screening 
Outliers:
• Age Range: 20-23
• 51-59% missing screening
• 6-10% of population lacking screening 
• BMI Group: BMI < 18.5
• 45-47% missing screening
• 2-3% of population lacking screening 
The Patient Problem: Target Demographics
Method: 




• Majority of studies 
took place in 
developed countries
Results:
• Invitation letters compared to 
control group
• RR = 1.44
• 95% CI: 1.24 – 1.52
• Face-to-face Education
• RR = 2.33
• 95% CI: 1.04 – 5.23
• Group Education
• RR = 1.92
• 95% CI: 1.24 – 2.97
Authors’ conclusions: 
• Evidence supports 
invitation letters to 
increase the uptake of 
cervical cancer 
screening. 
• Some evidence 
supports educational 
interventions; unclear 
what format is 
effective. 
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“Interventions targeted at women to 
encourage the uptake of cervical screening.” 
Everett, et al.
- Room for Improvement: 67.99% screening rate (2018)
- Opportunity for Impact: Represents 19.6% of HNNN population lacking screening (2017)




- Room for Improvement: 48.65% screening rate (2018)
- Opportunity for Impact: Represents 12.5% of HHHN population lacking screening (2017)
- Consistent target for improvement since 2016
Ticonderoga 
Health Center








Team Rewrite & 


















Notification that patient is due for screening
Invitation letters sent to 1075 patients
Costs: ~$650, including postage
What We Accomplished
Education regarding screening process
Invitation for patient to set appointment
Education regarding screening guidelines
Reminder that care is patient-centered





• Percent of eligible women at West Mountain 
Health Services 2 who underwent screening
• 2019 vs previous years 
Strengths
• Large sample size = greater power of possible 
results
• Utilizes well-studied methods for improving 
rates
Effectiveness, Strengths, and Limitations 
Limitations
• Time constraints
• Inability to personally follow up on results
• Cost limitations
• Led to elimination of CDC pamphlet
• Limited locations
• Sample size limited to West Mountain Health Services 2
• More rural areas left out




• With improved attribution, isolate provider demographic 
with continued poor screening rates
• Offer re-education on importance and method
Patient education
• Regular reminders
• Public Health Education Booth
• Personalized Reminder Letters
Data analysis of effectiveness of this program
• If successful
• develop continued initiative
• expand to other parts of HHHN
Recommendations for the Future
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